Methenamine hippurate - Urinary Tract Infection (UTIs)
You are here : Home > Formulary Search > Methenamine hippurate - Urinary Tract Infection (UTIs)
Status 1
- Tablets
For prevention of recurrent UTI in women over the age of 16 who are not pregnant
Status 2
- Tablets
Prescribe on specialist team recommendation for the following patient cohorts
- recurrent UTI of unknown cause
- recurrent UTI and suspected cance
- recurrent upper UTI
- recurrent lower UTI in: men, trans women and non-binary people with a male genitourinary system, who are aged 16 and over
- pregnant women, and pregnant trans men and non-binary people
- children and young people.
Documentation
PAD Profile
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed to a change in traffic light status for methenamine hippurate in the treatment of UTIs as follows:
GREEN traffic light status:
- In women (over the age of 16) who are not pregnant, as an alternative to avoid use of antibiotics if recurrent UTI has not been adequately improved by; vaginal oestrogen or single - dose antibiotics
BLUE (on specialist team recommendation) will still apply (agreed in September 2023) as a prophylaxis and treatment option for recurrent UTIs in men and women, outside of the cohort above.
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed methenamine hippurate as a prophylaxis and treatment option for recurrent UTIs in men and women.
Methenamine Hippurate will be given a BLUE (under specialist recommendation) for this indication.
This is an interim position and will be reviewed when NICE guidance on UTI prophylaxis is published.
The Antimicrobial Guidelines resources can be found here Guidelines : Antimicrobial guidelines - PAD Formulary (res-systems.net)
Other Indications
Below are listed other indications that Methenamine hippurate is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Urinary Tract Infection (UTIs).